Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03723915 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03723915 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 17 participants.
The verdict
NCT03723915, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well pembrolizumab in combination with pelareorep work in treating patients with pancreatic cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. A virus, called reovirus (pelareorep), which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. Giving pembrolizumab in combination with pelareorep may work better in treating patients with advanced pancreatic cancer.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Wild-type Reovirus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-11-14 |
| Est. Completion | 2021-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03723915
The ClinicalTrials.gov registry entry for NCT03723915 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03723915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03723915 about?
NCT03723915 is a clinical study titled "Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer". This phase II trial studies the side effects and how well pembrolizumab in combination with pelareorep work in treating patients with pancreatic cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body's immune...
What is the current status of trial NCT03723915?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2018-11-14. Estimated completion is 2021-04-24.
What interventions are being tested in trial NCT03723915?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Wild-type Reovirus (BIOLOGICAL).
Who is sponsoring clinical trial NCT03723915?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.